http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2824785-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_21681305358f43ad55432b69c77c5f2d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-5751 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-665 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2228 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 |
| filingDate | 2017-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76beb5811420d2a244a765f4df1debd6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89bb0022af38ccd71591861ecbc8669b |
| publicationDate | 2021-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2824785-T3 |
| titleOfInvention | Procedures to determine whether a patient is likely to benefit from treatment with a therapeutic formulation |
| abstract | A method of determining whether a patient is likely to benefit from treatment with a therapeutic formulation, the method comprising the steps of: (a) determining the concentration of corticotropin-releasing hormone (CRH) in a sample from a patient prior to administration of the therapeutic formulation; (b) determining the CRH concentration in a sample from a patient after administration of the therapeutic formulation; and (c) comparing the pre-administration CRH concentration with the post-administration CRH concentration; where an increase in the patient's CRH concentration after administration indicates that the patient is likely to benefit from treatment with the therapeutic formulation and where no increase or decrease in the patient's CRH concentration after administration indicates that there is little the patient is likely to benefit from treatment with the therapeutic formulation; wherein the therapeutic formulation comprises CRH. |
| priorityDate | 2016-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 428.